1,4-丁二醇-¹³C₄ | 286012-95-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1,4-丁二醇-¹³C₄
• 英文名称: (~13~C_4_)Butane-1,4-diol
• 英文别名: (1,2,3,4-13C4)butane-1,4-diol
• CAS: 286012-95-1
• 化学式: C4H10O2
• 分子量: 94.092
• InChiKey: WERYXYBDKMZEQL-JCDJMFQYSA-N

物化性质

• 熔点：
  16 °C(lit.)
• 沸点：
  230 °C(lit.)
• 密度：
  1.061 g/mL at 25 °C

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  6
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  叔丁基二苯基氯硅烷 、 1,4-丁二醇-¹³C₄ 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 以97 %的产率得到
  参考文献：
  名称：

  SELECTION OF PATIENTS FOR THE TREATMENT OF FADS1-MEDIATED DISEASES OR DISORDERS USING FADS-1 INHIBITORS

  摘要：

  The present disclosure provides techniques for accessing FADS1 activity in a patient. Also provided are techniques for determining the appropriateness of treatment of a patient with a FADS1 modulating (e.g., inhibiting) compound. This determination may be made by analyzing one or more biological indicators of FADS1-mediated disease or disorder in the subject. The one or more biological indicators may include one or more of a ratio of polyunsaturated fatty acids ("PUFAs") in the subject, a relative abundance of one or more cell types, a relative abundance of one or more differentially expressed genes ("DEGs") (or gene signatures, such as RNA, for such DEGs), and/or a relative abundance of one or more metabolites. Also disclosed are methods of using FADS1 inhibitors in methods of treating metabolic disorders and obesity.

  公开号：

  WO2024112763A1

文献信息

• SELECTION OF PATIENTS FOR THE TREATMENT OF FADS1-MEDIATED DISEASES OR DISORDERS USING FADS-1 INHIBITORS
  申请人：[en]AMGEN INC.

  公开号：WO2024112763A1

  公开（公告）日：2024-05-30

  The present disclosure provides techniques for accessing FADS1 activity in a patient. Also provided are techniques for determining the appropriateness of treatment of a patient with a FADS1 modulating (e.g., inhibiting) compound. This determination may be made by analyzing one or more biological indicators of FADS1-mediated disease or disorder in the subject. The one or more biological indicators may include one or more of a ratio of polyunsaturated fatty acids ("PUFAs") in the subject, a relative abundance of one or more cell types, a relative abundance of one or more differentially expressed genes ("DEGs") (or gene signatures, such as RNA, for such DEGs), and/or a relative abundance of one or more metabolites. Also disclosed are methods of using FADS1 inhibitors in methods of treating metabolic disorders and obesity.